The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index.
Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833
Abstract
The current study assessed whether the chronic constriction injury (CCI) model of neuropathic pain causes depression-like behaviour in animals, and if this depression-like behaviour can be reversed by anti-nociceptive and/or antidepressant drugs. CCI of the sciatic nerve in rats was selected as a neuropathic pain model, mechanical hypersensitivity was assessed by punctuate mechanical stimuli, and depression-like behaviour was evaluated in the forced swimming test (FST) measuring the time of immobility, climbing and swimming. The CCI rats displayed a significant mechanical hypersensitivity (sham 27+/-2g, CCI 12+/-2g; P<0.001) and a significant increase in time of immobility (sham 133+/-14s, CCI 201+/-9s; P<0.001). As time of swimming was unchanged, immobility was increased at the expense of climbing behaviour (sham 105+/-17s, CCI 63+/-9s; P<0.05). There was no difference in ambulation between sham and CCI animals. In sham and CCI animals, desipramine (20mg/kg) significantly reduced immobility (sham+vehicle 134+/-19s, sham+desipramine 79+/-13s; P<0.01, CCI+vehicle 195+/-8s, CCI+desipramine 140+/-11s; P<0.05) and increased climbing behaviour (sham+vehicle 118+/-21s, sham+desipramine 182+/-16s; P<0.05, CCI+vehicle 59+/-8s, CCI+desipramine 112+/-14s; P<0.05) with little effect on mechanical hypersensitivity. In contrast in CCI animals the cannabinoid CB2-selective agonist GW405833 (2,3-dichloro-phenyl)-[5-methoxy-2-methyl-3-(2-morpholin-4-yl-ethyl)-indol-1-yl]-methanone) (30 mg/kg) significantly attenuated immobility (CCI+vehicle 191+/-7s, GW405833 145+/-14s; P<0.01) and mechanical hypersensitivity (CCI+vehicle 15+/-1g, CCI+GW405833 24+/-1g; P<0.001). Moreover, differently from desipramine, GW405833 did not change the climbing behaviour. These data suggest that rats subjected to the CCI model of neuropathic pain develop depression-like behaviour, which can be reversed by appropriate anti-nociceptive treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, GW405833, a CB2-specific agonist, also reduces depression-like behavior associated with this mononeuropathy in the forced swim test.50”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [50]
Citations
Cites
Ethical guidelines for investigations of experimental pain in conscious animals.
Zimmermann, M. (1983) · Pain · doi:10.1016/0304-3959(83)90201-4 · Cited by 7,762
A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man
Bennett, G. J., & Xie, Y.-K. (1988) · Pain · doi:10.1016/0304-3959(88)90209-6 · Cited by 5,376
Depression and Pain Comorbidity: A Literature Review
Bair, M. J., Robinson, R. L., Katon, W., & Kroenke, K. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.20.2433 · Cited by 3,463
Pharmacologic management of neuropathic pain: Evidence-based recommendations
Dworkin, R. H., O’Connor, A. B., Backonja, M., Farrar, J. T., Finnerup, N. B., Jensen, T. S., Kalso, E. A., Loeser, J. D., Miaskowski, C., Nurmikko, T. J., et al. (2007) · Pain · doi:10.1016/j.pain.2007.08.033 · Cited by 2,126
Assessing antidepressant activity in rodents: recent developments and future needs
Cryan, J. F., Markou, A., & Lucki, I. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02017-5 · Cited by 1,551 · cited 3×
“In the FST, climbing and swimming active behaviours are selectively altered by the noradrenergic and serotonergic systems, respectively [6,7,21].”
BackgroundMethodQuantitative sensory testing: a comprehensive protocol for clinical trials
Rolke, R., Magerl, W., Andrews, K., Schalber, C., Caspari, S. S., Birklein, F., & Treede, R. (2005) · European Journal of Pain · doi:10.1016/j.ejpain.2005.02.003 · Cited by 1,521
Detke, M. J., Rickels, M. R., & Lucki, I. (1995) · Psychopharmacology · doi:10.1007/bf02245592 · Cited by 1,466
From the gate to the neuromatrix
Melzack, R. (1999) · Pain · doi:10.1016/s0304-3959(99)00145-1 · Cited by 1,170
Sindrup, S. H., & Jensen, T. S. (1999) · Pain · doi:10.1016/s0304-3959(99)00154-2 · Cited by 1,142
EFNS guidelines on pharmacological treatment of neuropathic pain
Attal, N., Cruccu, G., Haanpää, M. L., Hansson, P. T., Jensen, T. S., Nurmikko, T. J., Sampaio, C., Sindrup, S. H., & Wiffen, P. J. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01511.x · Cited by 877
Cited by
Sorted by citations
Items 101–141 of 141
Borgonetti, V., Mugnaini, C., Corelli, F., & Galeotti, N. (2023) · Biomedicines · doi:10.3390/biomedicines11061546 · Cited by 11
Gao, K.-X., Zhao, Q. C., Wang, G.-R., Yu, L., Wu, J., & Zhao, X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00318 · Cited by 11
Anandamide as a Therapeutic Target for Alleviating Neuropathic Pain and Inflammation in Rat Models
Sharma, H., Khan, S., Lohani, A., Chandra, P., Sachan, N., & Baldi, A. (2025) · Current Neurovascular Research · doi:10.2174/0115672026391315250822063941 · Cited by 12
Austin, P. J., Bembrick, A. L., Denyer, G. S., & Keay, K. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124755 · Cited by 10
The Endocannabinoid System in Prefrontal Synaptopathies
Scheyer, A. F., Martin, H. G. S., & Manzoni, O. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-57371-7_7 · Cited by 10
The Role of Exercise on Glial Cell Activity in Neuropathic Pain Management
Vieira, W. F., Real, C. C., Martins, D. O., & Chacur, M. (2025) · Cells · doi:10.3390/cells14070487 · Cited by 11
Bai, X., Batallé, G., Martínez-Martel, I., & Pol, O. (2023) · Antioxidants · doi:10.3390/antiox12061179 · Cited by 9
Sharma, P., Daksh, R., Khanna, S., Mudgal, J., Lewis, S. A., Arora, D. S., & Nampoothiri, M. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177422 · Cited by 8
Wu, J., Wang, Y., Cui, W., Zhou, W., & Zhao, X. (2020) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2020-101472 · Cited by 7
Novel targets in pain research: The case for CB2 receptors as a biorational pain target
Brownjohn, P. W., & Ashton, J. C. (2009) · Current Anaesthesia and Critical Care · doi:10.1016/j.cacc.2009.07.014 · Cited by 7
Goswami, N., Aleem, M., & Manda, K. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113055 · Cited by 7
Cannabinoid type 2 receptors play a crucial role in social defeat-induced depression
Chen, X., Yu, R., Chen, J., Wang, J., Huang, H., Li, H., Wu, G.-C., Han, Q.-Q., & Yu, J. M. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.12.089 · Cited by 7
Brugnatelli, V., Facco, E., & Zanette, G. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.565633 · Cited by 6
The lateral Habenula: Role in Chronic Pain and Depression
Zhang, G.-F., Guo, J., & Yang, J. (2020) · Translational Perioperative and Pain Medicine · doi:10.31480/2330-4871/126 · Cited by 5
Cannabinoids and Huntington’s disease
Casteels, C., Ahmad, R. U., Vandenbulcke, M., Vandenberghe, W., & Laere, K. V. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417041-4.00004-7 · Cited by 5
Animal Models of Neuropathic Pain Due to Nerve Injury
Austin, P. J., & Moalem‐Taylor, G. (2012) · Neuromethods · doi:10.1007/978-1-62703-233-9_14 · Cited by 4
Novel azoles as potent and selective cannabinoid CB2 receptor agonists
Harnett, J. J., Dolo, C., Viossat, I., Auger, F., Ferrandis, E., Bigg, D. C. H., Auguet, M., Auvin, S., & Chabrier, P. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.11.003 · Cited by 4
Johnson, E. E., & Ervasti, J. M. (2025) · FEBS Journal · doi:10.1111/febs.70029 · Cited by 2
Brito, D. T. P., Medeiros, A. C., Leite‐Panissi, C. R. A., Cárnio, E. C., Machado, H. R., Coimbra, N. C., de Freitas, R. L., & de Medeiros, P. S. (2025) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-025-01751-w · Cited by 2
Brain Imaging of Cannabinoid Receptors
Casteels, C., Bormans, G. M., & Laere, K. V. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-418677-4.00003-8 · Cited by 2
The Ups and Downs of Endocannabinoid Signaling in Chronic Pain-Induced Depression
Wilkinson, N. (2022) · Journal of Neuroscience · doi:10.1523/jneurosci.2212-21.2022 · Cited by 2
Sánchez-Florentino, Z. A., Romero-Martínez, B. S., Flores‐Soto, E., Serrano, H., Montaño, L., Valdés‐Tovar, M., Calixto, E., Aquino‐Gálvez, A., López-Riquelme, G. O., Alvarado, R., et al. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5331 · Cited by 2
Acunha, R. M., Medeiros, P., Machado, H. R., Sbragia, L., Coimbra, N. C., Maione, S., & de Freitas, R. L. (2026) · Physiology & Behavior · doi:10.1016/j.physbeh.2026.115374 · Cited by 1
RetractedThe Management of Neuropathic Pain
Toth, C., & Moulin, D. E. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139152211.019 · Cited by 1
[A psychosomatic theory of allergic sensitization; allergy as a quasi conditioned reaction].
Hansen, O. (1981) · PubMed · Cited by 1
Duloxetine usage in depression
Hu, B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817933-8.00094-3 · Cited by 1
Rouwette, T., Vanelderen, P., Roubos, E. W., Kozicz, T., & Vissers, K. C. P. (2013) · Neuropraxis · doi:10.1007/s12474-013-0002-3
Ware, M. A. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139152211.022
Leite‐Almeida, H. (2011) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Patel, H. P. (2016) · CU Scholar (University of Colorado Boulder)
Behavioural Co-morbidities in Rat Models of Neuropathic Pain
Legg, E. D. (2011) · Spiral (Imperial College London) · doi:10.25560/9070
Elsayed, A.-S. E., Awadin, W. F., Abass, M., & Hamed, M. F. (2019) · Kafrelsheikh Veterinary Medical Journal · doi:10.21608/kvmj.2019.110202
A Review on the Pain and Depression Comorbidity Animal Models
Song, J.-H., Kook, H. J., Park, B., Kim, S., & Park, J.-Y. (2021) · Korean Journal of Acupuncture · doi:10.14406/acu.2021.010
Medeiros, A. C. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2021.tde-06122021-145206
Neuropathic pain and depression : molecular alterations in the anterior cingulate cortex
Humo, M. (2019) · theses.fr (ABES) · doi:10.70675/e72f9364z66cbz45c4z8b42zb7f3564cd3d0
Contribution of the amygdalo-cingulate pathway in depression and its comorbidity with chronic pain
Becker, L. J. (2021) · theses.fr (ABES) · doi:10.70675/cdeda10fz3bbdz4a8cza740z361352fc379b
Abdallah, K., & Yalçın, İ. (2025) · Dunod eBooks · doi:10.3917/dunod.poisb.2025.01.0841
BindingDB Entry 50045995: Novel azoles as potent and selective cannabinoid CB2 receptor agonists.
BindingDB (2016) · UC San Diego · doi:10.7270/q2736sn4
Metadata
- Authors
- Hu, B., Doods, H., Treede, R.-D., & Ceci, A.
- Affiliations
- Boehringer Ingelheim (Germany) (DE)
- Heidelberg University (DE)
- Corresponding author
- Ceci, Angelo
- Venue
- Pain
- Published
- 2009-06
- Volume
- 143
- Issue
- 3
- Pages
- 206-212
- ISSN
- 0304-3959 (ISSN-L)
- OpenAlex
- W2001545679
- Cited by
- 138
- References
- 44
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 3 · 2023: 4 · 2022: 5 · 2021: 11 · 2020: 17 · 2019: 8 · 2018: 6 · 2017: 6 · 2016: 8 · 2015: 15 · 2014: 9 · 2013: 11 · 2012: 6
- FWCI
- 5.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pain (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bundesministerium für Bildung und Forschung
- Topics
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- CB2 receptor agonist, neuropathic pain, depression-like behavior, chronic constriction injury, sciatic nerve, forced swim test, immobility, desipramine, mechanical hypersensitivity, cannabinoid therapy, antidepressant effects, nociception, rats, pain-depression comorbidity, neuroinflammation, neuroprotection, neurogenesis, neuroplasticity
- MeSH terms
- Animals, Antidepressive Agents, Antidepressive Agents, Tricyclic, Behavior, Animal, Depressive Disorder, Desipramine, Disease Models, Animal, Exploratory Behavior, Hyperalgesia, Indoles, Ligation, Male, Morpholines, Motor Activity, Neuralgia, Neuropsychological Tests, Pain Measurement, Peripheral Nervous System Diseases, Swimming, Treatment Outcome, Rats, Wistar, Sciatic Neuropathy, Receptor, Cannabinoid, CB2, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review